Dr. Hanmei Xu Prof. of China Pharmaceutical University, Head of The Engineering Research Center of Peptide Drug Discovery and Development. Dr. Xu has been funded by the government for more than six times in recent five years, and whose research focuses on Design, screening and druggability evaluation of peptide drugs including anti-tumor, anti-rheumatoid arthritis, anti-pulmonary fibrosis and anti-acute inflammation drugs. Improvement of peptide drug effectiveness by biochemical modifications, e.g. PEGylation, fusion with IgG Fc part, connection to HSA, etc. Dr. Xu’s discoveries and efforts helped the companies to exploit four class one peptide drug. In recent five years, she published more than 70 papers, including 29 SCI papers about peptide, and applied for 39 patents of innovation, of which 15 have been authorized. As the Chair of "The 14th Chinese International Peptide Symposium & the 5th Asia-pacific International Peptide Symposium " in 2016, she successfully organized the Conference. Her group focuses on peptide-based drug and biomaterial design, in the recent five years, they undertook seven National Science and Technology Major Projects of New Drugs. The group got Science and Technology Progress Award with the work “The innovative techniques for peptide drug discovery and development” in December 2014. 80 papers were published in the last five years including 60 SCI papers. Her group applied 52 patents including 5 international patents, of which 21 have been authorized in China. The group have several joint programs with companies and the work improved the ability to discover and develop peptide drugs in China.